To validate the possibility of S100A8 targeting against aggressive cancers, we have developed novel multivalent S100A8 competitive inhibitory peptides, and found that S100A8 competitive inhibitory peptides suppress both tumor progression and experimental tumor metastasis. Here, S100A8 is linked to neoplasm.